《FIGO 2018癌症报告》—子宫肉瘤诊治指南解读

2018-12-27 中国实用妇科与产科杂志.2018,34(12):1366-1371.

子宫肉瘤约占所有女性生殖道恶性肿瘤的1%,子宫体恶性肿瘤的3%~7%。因其罕见和组织病理学的多样性,目前仍缺乏最佳治疗方案和与不良预后相关的危险因素的共识。 子宫肉瘤的亚型有平滑肌肉瘤、子宫内膜间质肉瘤(ESS)和子宫腺肉瘤。目前,癌肉瘤被认为是去分化的子宫内膜癌或者转化型子宫内膜癌。因为癌肉瘤较常见类型的子宫内膜癌更具侵袭性,目前绝大多数研究者仍将癌肉瘤和子宫肉瘤放在一起进行分析。 《FIGO

中文标题:

《FIGO 2018癌症报告》—子宫肉瘤诊治指南解读

发布机构:

发布日期:

2018-12-27

简要介绍:

子宫肉瘤约占所有女性生殖道恶性肿瘤的1%,子宫体恶性肿瘤的3%~7%。因其罕见和组织病理学的多样性,目前仍缺乏最佳治疗方案和与不良预后相关的危险因素的共识。 子宫肉瘤的亚型有平滑肌肉瘤、子宫内膜间质肉瘤(ESS)和子宫腺肉瘤。目前,癌肉瘤被认为是去分化的子宫内膜癌或者转化型子宫内膜癌。因为癌肉瘤较常见类型的子宫内膜癌更具侵袭性,目前绝大多数研究者仍将癌肉瘤和子宫肉瘤放在一起进行分析。 《FIGO 2018癌症报告》——子宫肉瘤诊治指南也纳入了癌肉瘤内容。肿瘤分期是子宫肉瘤最重要的预后因素。长期使用他莫昔芬可使子宫肉瘤的发病风险增加3倍。有因其他部位肿瘤的放射治疗引起继发肉瘤的病例报道。无论是超声检查还是PET扫描,在术前都难以分辨平滑肌瘤的良恶性。磁共振弥散加权成像(DWI)对肿瘤的部位和定性有帮助,但结果尚待证实。癌肉瘤和腺肉瘤发病年龄明显大于其他肉瘤患者。

作者: 中山大学孙逸仙纪念医院妇科 梁金晓 林仲秋

拓展指南:子宫肉瘤相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=《FIGO 2018癌症报告》—子宫肉瘤诊治指南解读)] GetToolGuiderByIdResponse(projectId=1, id=1558f1c00168a33c, title=《FIGO 2018癌症报告》—子宫肉瘤诊治指南解读, enTitle=, guiderFrom=中国实用妇科与产科杂志.2018,34(12):1366-1371., authorId=null, author=, summary=子宫肉瘤约占所有女性生殖道恶性肿瘤的1%,子宫体恶性肿瘤的3%~7%。因其罕见和组织病理学的多样性,目前仍缺乏最佳治疗方案和与不良预后相关的危险因素的共识。 子宫肉瘤的亚型有平滑肌肉瘤、子宫内膜间质肉瘤(ESS)和子宫腺肉瘤。目前,癌肉瘤被认为是去分化的子宫内膜癌或者转化型子宫内膜癌。因为癌肉瘤较常见类型的子宫内膜癌更具侵袭性,目前绝大多数研究者仍将癌肉瘤和子宫肉瘤放在一起进行分析。 《FIGO , cover=, journalId=null, articlesId=null, associationId=null, associationName=, associationIntro=, copyright=0, guiderPublishedTime=Thu Dec 27 00:00:00 CST 2018, originalUrl=, linkOutUrl=, content=<div>子宫肉瘤约占所有女性生殖道恶性肿瘤的1%,子宫体恶性肿瘤的3%~7%。因其罕见和组织病理学的多样性,目前仍缺乏最佳治疗方案和与不良预后相关的危险因素的共识。 子宫肉瘤的亚型有平滑肌肉瘤、子宫内膜间质肉瘤(ESS)和子宫腺肉瘤。目前,癌肉瘤被认为是去分化的子宫内膜癌或者转化型子宫内膜癌。因为癌肉瘤较常见类型的子宫内膜癌更具侵袭性,目前绝大多数研究者仍将癌肉瘤和子宫肉瘤放在一起进行分析。 《FIGO 2018癌症报告》——子宫肉瘤诊治指南也纳入了癌肉瘤内容。肿瘤分期是子宫肉瘤最重要的预后因素。长期使用他莫昔芬可使子宫肉瘤的发病风险增加3倍。有因其他部位肿瘤的放射治疗引起继发肉瘤的病例报道。无论是超声检查还是PET扫描,在术前都难以分辨平滑肌瘤的良恶性。磁共振弥散加权成像(DWI)对肿瘤的部位和定性有帮助,但结果尚待证实。癌肉瘤和腺肉瘤发病年龄明显大于其他肉瘤患者。</div> <div><br> </div>作者: 中山大学孙逸仙纪念医院妇科 梁金晓 林仲秋 <div><br> </div> 拓展指南:<strong>与<font color=red>子宫肉瘤</font>相关指南:</strong><br><ul><li><a href="http://www.medsci.cn/guideline/show_article.do?id=fe0191c00165815b" title="子宫肉瘤诊断与治疗指南(第四版)" target=_blank>子宫肉瘤诊断与治疗指南(第四版)</a></li> 更多信息请点击:<a href="http://www.medsci.cn/guideline/list.do?q=%E5%AD%90%E5%AE%AB%E8%82%89%E7%98%A4" target=_blank>有关子宫肉瘤更多指南</a></ul>, tagList=[TagDto(tagId=72322, tagName=癌症报告)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=36, categoryName=妇产科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=解读, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=8361, appHits=273, showAppHits=10, pcHits=6555, showPcHits=2504, likes=215, shares=14, comments=4, approvalStatus=1, publishedTime=Sun Jan 06 20:18:38 CST 2019, publishedTimeString=2018-12-27, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Sun Jan 06 20:18:38 CST 2019, updatedBy=null, updatedName=null, updatedTime=Thu Jan 04 23:00:08 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=《FIGO 2018癌症报告》—子宫肉瘤诊治指南解读)])
《FIGO 2018癌症报告》—子宫肉瘤诊治指南解读
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=954751, encodeId=8a51954e51e3, content=已看,还可以。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bc65476534, createdName=ms6000001015893838, createdTime=Wed Apr 07 15:05:21 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804267, encodeId=f94e80426e17, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b165282387, createdName=14846bbem56暂无昵称, createdTime=Fri Jul 24 10:33:54 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=357406, encodeId=e46935e406b1, content=谢谢分享,学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Mon Jan 07 08:21:09 CST 2019, time=2019-01-07, status=1, ipAttribution=)]
    2021-04-07 ms6000001015893838

    已看,还可以。

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=954751, encodeId=8a51954e51e3, content=已看,还可以。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bc65476534, createdName=ms6000001015893838, createdTime=Wed Apr 07 15:05:21 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804267, encodeId=f94e80426e17, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b165282387, createdName=14846bbem56暂无昵称, createdTime=Fri Jul 24 10:33:54 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=357406, encodeId=e46935e406b1, content=谢谢分享,学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Mon Jan 07 08:21:09 CST 2019, time=2019-01-07, status=1, ipAttribution=)]
    2020-07-24 14846bbem56暂无昵称

    谢谢

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=954751, encodeId=8a51954e51e3, content=已看,还可以。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bc65476534, createdName=ms6000001015893838, createdTime=Wed Apr 07 15:05:21 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804267, encodeId=f94e80426e17, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b165282387, createdName=14846bbem56暂无昵称, createdTime=Fri Jul 24 10:33:54 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=357406, encodeId=e46935e406b1, content=谢谢分享,学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Mon Jan 07 08:21:09 CST 2019, time=2019-01-07, status=1, ipAttribution=)]
    2019-01-07 明月清辉

    谢谢分享,学习了

    0